Plain-English translation of NCT06902376 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a combination of two medications — and — given before surgery to patients with anaplastic thyroid cancer that does not have a specific BRAF mutation. The study wants to see if this combination is safe and helps shrink the cancer before surgery, making the operation more successful.
Anaplastic thyroid cancer is a very aggressive disease with limited treatment options. Currently, chemotherapy is standard care but doesn't work well for many patients. This trial tests whether combining two newer types of medication—one that blocks cancer cell growth and one that boosts the immune system—works better than what's available now.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive the two medications by infusion before your scheduled surgery. You will have regular visits to check how you're tolerating the treatment and how your cancer is responding. After surgery, your doctor may recommend additional treatment based on what they find during the operation. The study is designed to include about 12 patients total.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States